LLY's Phase III Study on Jaypirca in Front-Line Leukemia Meets Goal

Key Takeaways Lilly's phase III BRUIN CLL-313 trial met its main goal with Jaypirca in untreated CLL/SLL patients.Jaypirca delivered a significant progression-free survival benefit versus chemoimmunotherapy.Overall survival trended favorably for Jaypirca, with final analysis expected in 2026.Eli Lilly (LLY) announced that the phase III BRUIN CLL-313 study, evaluating its BTK inhibitor Jaypirca (pirtobrutinib) versus chemoimmunotherapy (bendamustine plus rituximab) in treatment-naïve patients with chronic ly ...